OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
The FDA has finalized its guidance on interchangeable biosimilars, but the new specifications will still make it a difficult for biosimilar producers looking to make headway in the United States. GlobalData’s Senior Immunology Pharma Analyst, Rose Joachim, weighs in.
See what she has to say here.